We have some amazing news to share with our network today, following an announcement this morning from the Australian Government. People living with HER2-low metastatic breast cancer will, from 1 September 2024, have access to the life-prolonging drug Enhertu (trastuzumab deruxtecan) through the Pharmaceutical Benefits…
The Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the drug Enhertu (trastuzumab deruxtecan) for people with HER2-low metastatic breast cancer (MBC) to be subsidised on the Pharmaceutical Benefits Scheme (PBS). We now call on the Australian Government to work with the pharmaceutical company to list…